昭衍新药
(603127)
| 流通市值：309.46亿 | | | 总市值：369.43亿 |
| 流通股本：6.28亿 | | | 总股本：7.49亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 703,819,032.13 | 316,135,036.49 | 1,657,624,302.72 | 984,961,529.76 |
| 营业总成本 | 712,008,600.24 | 334,230,289.38 | 1,663,214,563.55 | 1,025,427,901.11 |
| 其他经营收益 | | | | |
| 营业利润 | 815,300,032.86 | 255,919,438.28 | 337,991,117.87 | 99,452,028.34 |
| 利润总额 | 815,243,157.94 | 256,055,391.68 | 337,493,264.97 | 99,625,384.82 |
| 净利润 | 747,518,791.03 | 238,351,421.53 | 297,842,526.3 | 80,706,047.32 |
| 每股收益 | | | | |
| 其他综合收益 | -12,948,683.47 | -6,579,713.78 | -19,287,775 | -6,480,220.42 |
| 综合收益总额 | 734,570,107.56 | 231,771,707.75 | 278,554,751.3 | 74,225,826.9 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 6,502,550,557.39 | 5,067,305,682.98 | 5,262,235,725.99 | 5,313,064,269.17 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,323,488,121.34 | 4,969,560,173.23 | 4,419,672,895.25 | 4,220,318,440.05 |
| 资产总计 | 10,826,038,678.73 | 10,036,865,856.21 | 9,681,908,621.24 | 9,533,382,709.22 |
| 流动负债: | | | | |
| 流动负债合计 | 1,605,370,735.02 | 1,261,544,583.08 | 1,160,587,930.7 | 1,220,473,990.19 |
| 非流动负债: | | | | |
| 非流动负债合计 | 245,321,887.94 | 218,198,404.3 | 195,969,529.46 | 191,886,482.35 |
| 负债合计 | 1,850,692,622.96 | 1,479,742,987.38 | 1,356,557,460.16 | 1,412,360,472.54 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 8,974,973,551.73 | 8,556,756,955.86 | 8,324,980,015.06 | 8,120,652,590.12 |
| 股东权益合计 | 8,975,346,055.77 | 8,557,122,868.83 | 8,325,351,161.08 | 8,121,022,236.68 |
| 负债和股东权益合计 | 10,826,038,678.73 | 10,036,865,856.21 | 9,681,908,621.24 | 9,533,382,709.22 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,256,505,013.06 | 556,847,904.04 | 1,832,127,321.85 | 1,323,471,987.19 |
| 经营活动现金流出小计 | 799,291,114.2 | 429,236,740.96 | 1,387,560,599.72 | 1,057,080,837.87 |
| 经营活动产生的现金流量净额 | 457,213,898.86 | 127,611,163.08 | 444,566,722.13 | 266,391,149.32 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,505,599,299.74 | 1,437,096,756.62 | 2,370,511,751.39 | 1,966,983,491.98 |
| 投资活动现金流出小计 | 2,998,064,245.91 | 1,479,283,452.94 | 2,789,704,697.22 | 2,231,706,104.47 |
| 投资活动产生的现金流量净额 | -492,464,946.17 | -42,186,696.32 | -419,192,945.83 | -264,722,612.49 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 50,221,515 | - | - | - |
| 筹资活动现金流出小计 | 85,847,634.64 | 5,447,459.82 | 66,984,055.31 | 58,988,545.91 |
| 筹资活动产生的现金流量净额 | -35,626,119.64 | -5,447,459.82 | -66,984,055.31 | -58,988,545.91 |
| 汇率变动对现金及现金等价物的影响 | -17,041,736.06 | -8,746,427.18 | -11,738,509.02 | -5,822,610.67 |
| 现金及现金等价物净增加额 | -87,918,903.01 | 71,230,579.76 | -53,348,788.03 | -63,142,619.75 |
| 期末现金及现金等价物余额 | 823,935,437.55 | 983,084,920.32 | 911,854,340.56 | 902,060,508.84 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -87,918,903.01 | - | -53,348,788.03 | - |
最新报告期：2026-09-07| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中信建投 | 袁清慧 | 1.45 | 0.81 | 1.10 | 2026-09-07 |
| 国信证券 | 彭思宇,陈曦炳 | 1.49 | 0.95 | 1.17 | 2026-09-02 |
| 中金公司 | 俞波,张琎,吴婉桦 | 1.11 | 0.53 | -- | 2026-08-30 |
| 华泰证券 | 代雯,高鹏 | 1.24 | 1.04 | 1.28 | 2026-08-28 |